Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen is awarded a research grant from “Regione Toscana”

Dec 23, 2015 | 2015, Press Releases, Scientific

Philogen is awarded a research grant from “Regione Toscana” for a project focusing on the development of new strategies of Factor V purification for patients in need thereof. POSTER PROGETTO FV-OD

Dario Neri, the co-founder and Chairman of the Scientific Advisory Board presented at the 11th Annual European Antibody Congress in Basel, Switzerland, 9th-11th November.

Nov 9, 2015 | 2015, Past Events

Dario Neri, the co-founder and Chairman of the Scientific Advisory Board presented at the 11th Annual European Antibody Congress in Basel, Switzerland, 9th-11th November. The title of the talk was “Armed Antibodies for the treatment of Cancer and of Chronic...

Dario Neri, the co-founder and chairman of the scientific advisory board of Philogen will deliver the keynote speech at the First Boston Symposium of Encoded Library Platforms in Boston

Nov 6, 2015 | 2015, Past Events

Dario Neri, the co-founder and chairman of the scientific advisory board of Philogen will deliver the keynote speech at the First Boston Symposium of Encoded Library Platforms in Boston, 6th November. The title of his presentation will be “Single-Pharmacophore and...

Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim

Oct 12, 2015 | 2015, Press Releases, Scientific

Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia. Siena (Italy), October 12th. (see full Press Release).

Philogen. Data from Phase Ib clinical trial of Dekavil in rheumatoid arthritis

Sep 27, 2015 | 2015, Past Events

Philogen. Data from Phase Ib clinical trial of Dekavil in rheumatoid arthritis were presented at the 4th Israel-Italy Meeting of Autoimmunity and Autoinflammation: Cutting Edge. Siena (Italy), September 27th-28th.

Philogen attended BIO in Philadelphia, PA (USA), 15th-19th June, 2015.

Jun 12, 2015 | 2015, Past Events

« Older Entries

Recent Posts

  • Philogen to attend the European Bispecific and Multispecific Antibody congress in Amsterdam on the 22nd and 23rd of February, 2023
  • Philogen to attend the 7th Annual Next-Gen Immuno-Oncology Conference congress in London on the 9th and 10th of March, 2023
  • 23 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 16 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 09 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it